Overview
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Completed
Trial end date:
2020-11-01
2020-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Anavex Life Sciences Corp.
Criteria
Inclusion Criteria:- Previous exposure to ANAVEX2-73 via participation in Phase 2a Study of ANAVEX2-73
Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and
Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With
a 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)
Exclusion Criteria:
- Have not previously participated Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design
With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in
Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label
Follow-Up Period (ANAVEX2-73-002)